CA-RAFTR
16.3.2020 19:02:07 CET | Business Wire | Press release
Silicon Valley-based higher ed tech company Raftr announced today that it will offer its messaging and notifications platform free of charge through July 1, 2020 to colleges and universities, many of which are facing disruption and dislocation as a result of COVID-19 concerns. Each institution’s network is entirely private, limited to that community’s constituents.
The app facilitates immediate and direct communication between college administrations and their students in a mobile-first platform, enabling instant direct messaging to students’ mobile devices.
“Our partner institutions are facing a rapidly evolving COVID-19 outbreak, forcing unprecedented disruption on campuses and in remote learning environments,” Raftr Founder & CEO Sue Decker says. “The right thing to do is to offer our support. Raftr enables immediate communication between universities and their students, faculty, staff, and even parents, anywhere in the world. Exceptionally fast to implement, the interactive, flexible and coordinated communication platform can stand-alone or supplement email communication.”
Raftr enables group administrators to send custom push notifications directly to students’ and parents’ mobile devices, highlighting important updates about issues related to COVID-19, including online learning, study abroad cancellations or updates, academic information, and more.
Key features and customization options for different campus constituents include:
Administration:
- Public and private chat channels for sharing information, and Q&A in real time.
- Optional automatic posting of existing COVID-19 updates from authenticated sources, including CDC, the WHO, and/or existing university sources.
- Curated organization of all past communications for easy discovery and access.
Faculty:
- Ability to host real-time, virtual discussions and “office hours” in private channels for online courses, easily discoverable by students.
- Creation of an online lecture calendar with days / times of courses and ability to link directly to Zoom, Hangouts, or other online learning platforms.
- Direct and group chat options to stay connected to students one-on-one or in class settings.
- Ability to add links to important teaching materials.
Students:
- Creation of digital communities that mirror those on campus, including classes, student groups, social groups, and volunteer organizations.
- Ability to create unlimited public or private groups to maintain student organization communication and planning.
- Access to group chats, topic channels, direct messaging, photos & videos, polls and more.
Decker says the free use of the platform will be granted through July 1. To be eligible, administrators are asked to submit a request to enable their community and attend a one-hour online training session for any staff members who will be posting updates in the platform. Those staff members will be given access to Raftr ProTools, including the ability to send custom push notifications with important updates.
Online Request Form
Submit a request
Connect on Social
Twitter
LinkedIn
Facebook
About Raftr
Raftr promotes the power of belonging by building dynamic and safe digital communities through an intuitive student-centric communication platform. Each enabled school’s experience will be accessible only by that institution’s students, faculty, staff and parents, creating a private, curated, and trusted network. Raftr’s solutions cover every stage of undergraduate and alumni life, with packages for News & Events, Residence Life, Club & Groups / Academic Departments, and Orientation. The platform is available via mobile applications and website, and primary features include events, messaging, push notifications, polls and more. Additional information is available at https://pro.raftr.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005649/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
